Global Ropivacaine Market Forecast, Trend Analysis And Competition Tracking - Global Market insights 2015 to 2031

Global Ropivacaine Market Overview:

“The Ropivacaine Market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031.”

Ropivacaine is a local anesthetic that is used to provide extended surgical anesthesia and analgesia. It is a synthetic ester of ropivacaine hydrochloride and is often perceived as the most reliable agent for providing local anesthesia for outpatient procedures because it has a longer duration of action than other agents.

Other benefits include a lower concentration required, better penetration, and lower toxicity. It is often used in spinal anesthesia because it lowers allergies and systemic side effects. Ropivacaine depresses all levels of sensory transmission, including somatic, visceral, and sympathetic reflexes.

It improves the quality of epidural analgesia during labor by decreasing the need for augmentation or supplementing agents. Its main drawback is its propensity to cause systemic adverse reactions at higher doses.

The elderly population is also at higher risk of developing organ failure because of changes in pharmacodynamics related to age and organ function.

As the proportion of older patients increases, patients are at increased risk for heart and lung disease, altered kidney and liver function, and respiratory and urinary tract complications. The overall increase in the number of surgeries will have a strong impact on the anesthetics drugs market.

Increasing use of ropivacaine during surgeries

Ropivacaine is a local anesthetic medication that is often used during medical procedures because it leaves patients with less numbness, tingling, and itching of the skin.

Ropivacaine also has a slower onset and longer duration of action than many other local anesthetics, which means that it can be more easily controlled by the doctor administering the procedure. Ropivacaine is a commonly used epidural anesthetic that has been shown to decrease the side effects of anesthesia.

It is more potent than lidocaine and in some cases is administered with lidocaine, which is a local anesthetic in order to prevent systemic absorption.

Ropivacaine may be favored over other epidural anesthetics in patients susceptible to the side effects of anesthetics or in patients with a high risk of awareness during surgery.

Global Ropivacaine Market Restraints

High systemic doses of ropivacaine can cause central nervous system (CNS) and cardiovascular effects, with CNS effects typically occurring at lower plasma concentrations and additional cardiovascular effects occurring at higher concentrations.

However, cardiovascular collapse may occur at low concentrations. Central nervous system effects include central nervous system excitation, nervousness, tingling in the mouth, ringing in the ears, tremors, dizziness, blurred vision, and seizures.

CNS depression may occur, associated with somnolence, loss of consciousness, respiratory depression, and apnea.

Cardiovascular events may result from hypoxemia secondary to respiratory depression, including hypotension, bradycardia, arrhythmias, and/or cardiac arrest.

Opportunities for the Global Ropivacaine Market

The opportunity for drug development for ropivacaine is substantial because the molecule has low toxic effects, adequate analgesic potency, and a favorable pharmacokinetic profile.

Ropivacaine is an amide-type local anesthetic, which has been found to provide higher safety margins than bupivacaine when used for epidural anesthesia. The molecule has also been shown to exhibit less than 15% vasodilatory effects when used in clinical studies.

Global Ropivacaine Market Regional Analysis:

The North American region held the largest share in the global market for ropivacaine drugs owing to a significant number of surgical procedures performed in the region. In the U.S., over 1.7 million surgeries were performed with anesthesiologists present and accounted for almost half of all surgeries performed globally.

By July 2020, U.S. hospitals had ramped up surgery with improved safety protocols, and surgery rates were beginning to recover or even exceed 2019 levels. By the end of the year, the total number of surgeries was only 10% lower than in 2019.

Share of old age population (above 65 years) in the total U.S. population 2018-2020

Source: Prudour, 2021

Global Ropivacaine Market Competitive Landscape:

The Global Ropivacaine Market landscape appears highly consolidated, with a major chunk of it being dominated by players listed below:

• Pfizer, Inc.
• Apin Chemicals Limited
• NAVINTA LLC
• Akorn, Inc.
• Aurobindo Pharma Limited
• Teva Pharmaceutical Industries Ltd.
• Somerset Therapeutics, LLC
• SGPharma Pvt. Ltd.
• Nephron Pharmaceuticals
• SINTETICA SA Pharmaceuticals
• Other Key Industry Players

Report Scope

• Forecast Period: 2022-2031
• Actual Year: 2021
• Historical Data Available for: 2015-2020

Key Regions Covered

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Segments Covered

Ropivacaine Market, By Application

• Surgical Anesthesia
• Major Nerve Block
• labor Pain
• Other Applications

Ropivacaine Market, By End-Use

• Hospital
• Specialty Clinics
• Ambulatory Surgical Centers